Ignacio Jiménez Hernando

Ignacio Jiménez Hernando

Auto-generated profile, based on publicly available information

Ignacio Jiménez Hernando

Department of Endocrinology and Nutrition, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2026 in Endocrinología, Diabetes y Nutrición (English Ed.)
Verified
Journal Article
Closed access
IHIgnacio Jiménez Hernando
Ignacio Jiménez Hernando
ILIrene Bretón Lesmes
Irene Bretón Lesmes
AGArantxa Díaz Gómez
Arantxa Díaz Gómez
MCMiguel Sebastián Casallas Cepeda
Miguel Sebastián Casallas Cepeda
SCSantiago Salcedo Cortés
Santiago Salcedo Cortés

20 October 2026 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
IHIgnacio Jiménez Hernando
Ignacio Jiménez Hernando
AGAurelio López Guerra
Aurelio López Guerra
MGMaría Miguélez González
María Miguélez González
LGLaura González
Laura González
OAOlg Gonzalez Albarran
Olg Gonzalez Albarran
A 55-year-old man with hypercalcemic primary hyperparathyroidism underwent preprocedural localization with 99m Tc-MIBI SPECT/CT, demonstrating a right inferior parathyroid adenoma. As the patient refused surgery, radiofrequency ablation was performed. Calcium normalized progressively, while parathyroid hormone (PTH) levels remained mildly elevated at 6 months. Follow-up 99m Tc-MIBI SPECT/CT showed no residual adenomatous uptake, correctly predicting delayed biochemical cure, with subsequent normalization of PTH at 1 year. This case highlights the potential value of 99m Tc-MIBI SPECT/CT as an early imaging biomarker of therapeutic success after radiofrequency ablation in patients with persistent mild PTH elevation.

17 June 2024 in Endocrinología, Diabetes y Nutrición (English Ed.)
Verified
Journal Article
Closed access
IHIgnacio Jiménez Hernando
Ignacio Jiménez Hernando
LFLaura González Fernández
Laura González Fernández
JHJuan Carlos Percovich Hualpa
Juan Carlos Percovich Hualpa

1 July 2024
Verified
Journal Article
Open access
PDF file
IHIgnacio Jiménez Hernando
Ignacio Jiménez Hernando
LFLaura González Fernández
Laura González Fernández
The clinical case presented describes a 44-year-old woman with a history of mucinous carcinoma in the right breast, who is diagnosed with a pituitary adenoma. Physical examination revealed signs of acromegaly, such as macroglossia and palmar hyperhidrosis. Hormonal tests were performed and showed elevated levels of insulin-like growth factor type 1 (IGF-1). The patient received GnRH analogues for breast cancer; and started medical treatment with somatostatin analogues for acromegaly, which provided improvement in symptoms. Pituitary bleeding was detected during hormone treatment, which caused the growth of the adenoma, causing it to contact the optic chiasm, although no symptoms of pituitary apoplexy were present. Transsphenoidal endoscopic surgery was performed to remove the adenoma, and the diagnosis of pituitary adenoma was confirmed by pathology. The importance of the evaluation of comorbidities in patients with acromegaly is discussed. Pituitary apoplexy as an uncommon complication of pituitary adenomas, which may be associated with the use of GnRH analogues, is addressed. Pre-surgical medical treatment in acromegaly is also discussed, highlighting the importance of a comprehensive assessment of prognostic factors and appropriate treatment selection to improve clinical outcomes. In conclusion, the importance of a multidisciplinary and personalized approach in the management of patients with GH-producing pituitary adenomas to improve quality of life and clinical outcomes is highlighted.

1 May 2026
Verified
Journal Article
Closed access
IHIgnacio Jiménez Hernando
Ignacio Jiménez Hernando
MNMarta Pérez Noguero
Marta Pérez Noguero
MHMónica Gómez-Gordo Hernanz
Mónica Gómez-Gordo Hernanz
RCRogelio García Centeno
Rogelio García Centeno

8 May 2025 in Exploration of Endocrine and Metabolic Diseases
Verified
Journal Article
Open access
PDF file
IHIgnacio Jiménez Hernando
Ignacio Jiménez Hernando
LFLaura González Fernández
Laura González Fernández
MNMarta Pérez Noguero
Marta Pérez Noguero
Iatrogenic hypoparathyroidism is a serious complication that can arise from neck surgery, predominantly during thyroidectomy, parathyroidectomy, and laryngectomy; it can be transient or permanent, requiring lifelong treatment. Early detection and treatment are crucial to prevent severe hypocalcemia, which is potentially fatal. This case report describes a 59-year-old male with a history of well-differentiated squamous cell carcinoma of the vocal cords who developed severe postoperative hypoparathyroidism following total laryngectomy with right hemithyroidectomy. Despite initial treatment with cholecalciferol by nasogastric tube, the patient experienced recurrent severe hypocalcemia, requiring intravenous administration of calcitriol due to his inability to swallow. This case highlights the risk factors for triggering postoperative hypoparathyroidism, such as previous surgery or radiotherapy in the cervical region, underlines the importance of careful monitoring of postoperative hypoparathyroidism and proposes the use of intravenous calcitriol as an effective strategy in acute treatment when oral administration is not feasible.